You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Head and neck cancers

Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy

  • Technology appraisal guidance
  • Reference number: TA736
  • Published:  20 October 2021
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final draft guidance: TA736
  3. Draft guidance: TA736
  4. Invitation to participate
  5. Final draft guidance: TA490
  6. Draft guidance: TA490

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 140 KB)

    Published:
    20 October 2021

Final draft guidance: TA736

  • Final draft guidance: TA736

  • Final appraisal document (PDF 305 KB)

    Published:
    15 September 2021
  • Committee papers (PDF 1.9 MB)

    Published:
    15 September 2021
  • Public committee slides (PDF 776 KB)

    Published:
    15 September 2021

Draft guidance: TA736

  • Draft guidance: TA736

  • Appraisal consultation document (online commenting)

  • Appraisal consultation document (PDF version) (PDF 292 KB)

    Published:
    07 January 2021
  • Public committee slides (PDF 274 KB)

    Published:
    07 January 2021
  • Committee papers (PDF 3.58 MB)

    Published:
    07 January 2021

Invitation to participate

  • Final scope (PDF 157 KB)

    Published:
    30 January 2020
  • Final stakeholder list (PDF 187 KB)

    Published:
    30 January 2020

Final draft guidance: TA490

  • Committee papers TA490 (PDF 4.28 MB)

    Published:
    20 July 2023
  • Final appraisal document TA490 (PDF 454 KB)

    Published:
    20 July 2023

Draft guidance: TA490

  • Committee papers TA490 (PDF 13.25 MB)

    Published:
    20 July 2023
  • Appraisal consultation document (PDF version) TA490 (PDF 514 KB)

    Published:
    20 July 2023
Back to top